Publications

Publications Search

Search for publications by author
Search for publications by abstract keyword(s)

Dose considerations for anti-cancer drugs in metastatic prostate cancer

Abstract

Despite a growing number of treatment options, metastatic castrate resistant prostate cancer remains almost universally fatal. Dose individualization ensures patients receive the maximal benefit from each line of treatment potentially leading to improved outcomes, a reduction in quality of life impairment and minimization of premature cessation for avoidable toxicity. Herein, we review drug-specific issues that may be associated with unexpected or unrecognized variations in drug systemic exposure despite the use of protocol doses. In particular, we discuss the potential for under-exposure of docetaxel and cabazitaxel; over-exposure of enzalutamide; and varied absorption of abiraterone acetate.

Type Journal
ISBN 1097-0045 (Electronic) 0270-4137 (Linking)
Authors Crumbaker, M.; Gurney, H.
Responsible Garvan Author Megan Crumbaker
Publisher Name PROSTATE
Published Date 2017-08-31 00:00:00
Published Volume 77
Published Issue 11
Published Pages 1199-1204
Status Published in-print
DOI 10.1002/pros.23378
URL link to publisher's version https://www.ncbi.nlm.nih.gov/pubmed/28649702